Insider Stock Trading History of Hawran Paul W


The following table details the trading activities (stock purchases, stock sales, and stock option exercises) reported to the Securities and Exchange Commission (SEC) by insider Hawran Paul W since year 2005. The trader's CIK number is 1123344. At the time of this reporting, Hawran Paul W is the Chief Financial Offi of Cytori Therapeutics, Inc. . (stock ticker symbol XMPA). See this page for all insider trading activities at Cytori Therapeutics, Inc. .

Note that in the past HAWRAN PAUL W also reported insider trading activities as an insider of the following companies:
Stock purchases, sales, and option exercises reported by insider Hawran Paul W since 2005.
  Trade Date   Symbol Company Name (Issuer) Trade Type     Shares       Price ($)   Value ($)
2011-09-14 CYTX Cytori Therapeutics, Inc. Buy 5,000 3.20 16,020
2010-05-24 CYTX Cytori Therapeutics, Inc. Buy 5,000 4.65 23,235
2010-05-19 CYTX Cytori Therapeutics, Inc. Buy 5,000 4.83 24,165
2009-11-25 CYTX Cytori Therapeutics, Inc. Buy 5,000 4.90 24,500
2009-11-24 CYTX Cytori Therapeutics, Inc. Buy 5,000 4.74 23,700
2009-11-18 CYTX Cytori Therapeutics, Inc. Buy 20,000 4.24 84,900
2009-11-17 CYTX Cytori Therapeutics, Inc. Buy 5,000 3.98 19,900
2009-11-12 CYTX Cytori Therapeutics, Inc. Buy 10,000 3.50 35,000
2009-03-13 SQNM Sequenom Inc Buy 2,000 13.46 26,912
2009-03-04 SQNM Sequenom Inc Buy 5,000 13.45 67,250
2008-02-26 SQNM Sequenom Inc Buy 10,000 7.13 71,330
2007-11-05 SQNM Sequenom Inc Buy 10,000 8.83 88,320
2007-06-01 SQNM Sequenom Inc Buy 20,000 4.64 92,820
2007-05-22 SQNM Sequenom Inc Buy 10,000 3.97 39,670
2007-05-17 SQNM Sequenom Inc Buy 10,000 3.56 35,650
2007-05-10 SQNM Sequenom Inc Buy 10,000 3.18 31,850
2007-05-11 SQNM Sequenom Inc Buy 10,000 3.52 35,150
2006-05-17 NBIX Neurocrine Biosciences Inc Sale 115,481 19.98 2,306,963

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Hawran Paul W (Chief Financial Offi of Cytori Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.